Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers…